目的 探究三七通舒膠囊聯(lián)合阿司匹林治療老年冠心病的安全性及對(duì)凝血酶原時(shí)間國(guó)際標(biāo)準(zhǔn)化比率（PT-INR）、D-二聚體（D-D）、凝血酶原時(shí)間（PT）的影響。方法 選取綿陽市中醫(yī)醫(yī)院在2012年1月—2015年12月收治的、符合納入標(biāo)準(zhǔn)的老年冠心病患者90例。根據(jù)治療方法不同分為對(duì)照組（n=45）及觀察組（n=45）。對(duì)照組給予患者控制血壓、血糖、血脂等常規(guī)治療，同時(shí)口服拜阿司匹林0.1 g/次，1次/d，睡前服用；觀察組在對(duì)照組基礎(chǔ)上聯(lián)合三七通舒膠囊200 mg/次，3次/d；療程均為6個(gè)月。對(duì)比兩組治療前后PT-INR、D-D、PT、血小板聚集功能（PAgT）、肝腎功能指標(biāo)及不良反應(yīng)情況。結(jié)果 治療后，兩組PAgT及D-D降低，PT及PT-INR延長(zhǎng)，同組治療前后比較差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）；觀察組PAgT、PT、PT-INR均高于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組治療前后的丙氨酸氨基轉(zhuǎn)移酶（ALT）、天冬氨酸氨基轉(zhuǎn)移酶（AST）、血尿素氮（BUN）及血肌酐（Cr）差異無統(tǒng)計(jì)學(xué)意義。觀察組的不良反應(yīng)發(fā)生率（4.44%）明顯低于對(duì)照組（24.44%），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 三七通舒膠囊聯(lián)合阿司匹林治療老年冠心病是安全、有效的。

Objective To explore the effect of sanqi saponins on the safety of elderly patients with coronary heart disease and its effects on PT-INR, D-D and PT. Methods 90 elderly patients with coronary heart disease in our hospital from January 2012 to December 2015 were selected into the clinical data. The patients were divided into the control group (n=45) and the experimental group (n=45) by random number table. The control group was treated with aspirin, the experimental group was treated with Sanqi Tongshu Capsule. The PT-INR, D-D, PT, PAgT, liver and kidney indexes and adverse reactions were compared between the two groups before and after treatment. Results After treatment, PAgT and D-D decreased significantly (P<0.05), PT and PT-INR prolongation significantly (P<0.05). The PAgT, PT and PT-INR in the experimental group were higher than those in the control group (P<0.05). The difference of ALT, AST, BUN and Cr between the two groups before and after treatment were not statistically significant. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group (24.44% vs 4.44%, P=0.02). Conclusions Sanqi Tongshu Capsule is safe and effective in the treatment of senile coronary heart disease.

四川省科技攻關(guān)項(xiàng)目（2017JY0315）